THE US Food and Drug Administration has announced the approval of Zejula (niraparib) for maintenance treatment, intended to delay cancer growth, for adult patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer.
The above article was sent to subscribers in Pharmacy Daily's issue from 29 Mar 17
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 29 Mar 17
